Treatment of anemia with Aranesp™ (darbepoetin alfa) improves health related quality of life (HRQOL) in patients with chronic kidney disease (CKD).

被引：0
|
作者：
Thadhani, R
Cheriyan, R
Brenner, R
Ford, J
Powers, K
Rahman, SN
机构：
[1] Univ Texas, Hlth Sci Ctr, Houston, TX USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Virginia Nephrol Grp, Fairfax, VA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：637A / 637A
页数：1
相关论文
共 50 条
  • [21] A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE
    Roger, Simon D.
    Jassal, Sarbjit V.
    Woodward, Michael C.
    Soroka, Steven
    McMahon, Lawrence P.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (02) : 469 - 475
  • [22] A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE
    Simon D. Roger
    Sarbjit V. Jassal
    Michael C. Woodward
    Steven Soroka
    Lawrence P. McMahon
    International Urology and Nephrology, 2014, 46 : 469 - 475
  • [23] An extended terminal half-life for Aranesp® (darbepoetin alfa):: Results from a single-dose pharmacokinetic (PK) study in patients with chronic kidney disease (CKD)
    Padhi, D
    Jang, G
    Smith, B
    Marbury, T
    Cooke, B
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
  • [24] RESILIENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE - CKD
    Vinaccia, Stefano
    Margarita Quiceno, Japcy
    REVISTA ARGENTINA DE CLINICA PSICOLOGICA, 2011, 20 (03) : 201 - 211
  • [25] USE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) INSTRUMENTS IN CLINICAL TRIALS OF ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD)
    Mokiou, S.
    Hakimi, Z.
    Wang-Silvanto, J.
    Hollier-Hann, G.
    Moeller, A.
    VALUE IN HEALTH, 2018, 21 : S481 - S481
  • [26] Once-monthly Aranesp® (darbepoetin alfa) maintains hemoglobin in elderly chronic kidney disease patients.
    Ling, BN
    Agarwal, A
    Scarlata, D
    Brenner, R
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S24 - S25
  • [27] ECONOMIC EVALUATION OF EPOETIN ALFA HEXAL (BINOCRIT) COMPARED TO DARBEPOETIN ALFA (ARANESP) IN THE TREATMENT OF CHRONIC HAEMODIALYSIS (CKD5) PATIENTS IN GERMANY
    Turner, M.
    Walsh, K.
    Maerz, M.
    Whitehouse, J.
    VALUE IN HEALTH, 2013, 16 (07) : A631 - A631
  • [28] Aranesp® (Darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease.
    Walczyk, M
    Agarwal, A
    Ling, B
    Carroll, W
    Liu, W
    Brenner, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 770A - 770A
  • [29] ECONOMIC EVALUATION OF DARBEPOETIN ALFA AND EPOETIN IN HEMODIALYSIS PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE
    Vorobiev, P.
    Lesnicheva, M.
    Avksentieva, M.
    Nekrasova, N.
    VALUE IN HEALTH, 2009, 12 (03) : A134 - A134
  • [30] Anemia, inflammation and health-related quality of life in chronic kidney disease patients
    Farag, Y. M. K.
    Keithi-Reddy, S. R.
    Mittal, B. V.
    Surana, S. P.
    Addabbo, F.
    Goligorsky, M. S.
    Singh, A. K.
    CLINICAL NEPHROLOGY, 2011, 75 (06) : 524 - 533
12345